Impact of mycophenolic acid and tacrolimus on Th17-related immune response

Transplantation

Volumn 92, Issue 4, 2011, Pages 396-403

  Abadja, Farida ^a,b   Atemkeng, Stéphanie ^a,b   Alamartine, Eric ^a,b,c   Berthoux, François ^a,b,c   Mariat, Christophe ^a,b,c  

^a UNIVERSITÉ JEAN MONNET   (France)

^b UNIVERSITÉ DE LYON   (France)

^c HÔPITAL NORD   (France)

Author keywords

Immunosuppression; Interleukin 17; Kidney transplantation; Regulatory T cells T helper cells immune balance; Th17 cells

Indexed keywords

GAMMA INTERFERON; GENE PRODUCT; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 21; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORPHAN NUCLEAR RECEPTOR; T CELL IMMUNOGLOBULIN AND MUCIN DOMAIN 3; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; FOXP3 GENE; GAMMA INTERFERON GENE; GATA3 GENE; GENE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERLEUKIN 10 GENE; INTERLEUKIN 17 GENE; INTERLEUKIN 21 GENE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORPHAN NUCLEAR RECEPTOR GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TIM3 GENE; TRANSFORMING GROWTH FACTOR BETA GENE;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-17; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TACROLIMUS; TH17 CELLS;

EID: 80051724276     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182247b5f     Document Type: Article

References (39)

1. Cornell LD, Smith RN, Colvin RB. Kidney transplantation: Mechanisms of rejection and acceptance. Annu Rev Pathol 2008;3:189.
2. Strom TB, Koulmanda M. Recently discovered T cell subsets cannot keep their commitments. J Am Soc Nephrol 2009;20:1677.
3. van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549.
4. Pene J, Chevalier S, Preisser L, et al. Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes. J Immunol 2008;180:7423.
5. Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101.
6. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect 2009;11:625.
7. Deteix C, Attuil-Audenis V, Duthey A, et al. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol 2010;184:5344.
8. Yuan X, Paez-Cortez J, Schmitt-Knosalla I, et al. A novel role of CD4 Th17 cells in mediating cardiac allograft rejection and vasculopathy. J Exp Med 2008;205:3133.
9. Antonysamy MA, Fanslow WC, Fu F, et al. Evidence for a role of IL-17 in alloimmunity: A novel IL-17 antagonist promotes heart graft survival. Transplant Proc 1999;31:93. (Pubitemid 29127373)
10. Crispim JC, Grespan R, Martelli-Palomino G, et al. Interleukin-17 and kidney allograft outcome. Transplant Proc 2009;41:1562.
11. van Kooten C, Boonstra JG, Paape ME, et al. Interleukin-17 activates human renal epithelial cells in vitro and is expressed during renal allograft rejection. J Am Soc Nephrol 1998;9:1526.
12. Loong CC, Hsieh HG, Lui WY, et al. Evidence for the early involvement of interleukin 17 in human and experimental renal allograft rejection. J Pathol 2002;197:322.
13. Fabrega E, Lopez-Hoyos M, San Segundo D, et al. Changesinthe serum levels of interleukin-17/interleukin-23 during acute rejection in liver transplantation. Liver Transpl 2009;15:629.
14. Vanaudenaerde BM, Dupont LJ, Wuyts WA, et al. The role of interleukin-17 during acute rejection after lung transplantation. Eur Respir J 2006;27:779.
15. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T (H) 17 lineage. Nature 2006;441:231.
16. Veldhoen M, Hocking RJ, Atkins CJ, et al. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179.
17. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235.
18. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004;351:2715.
19. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 2009;9:1876.
20. Caretto D, Katzman SD, Villarino AV, et al. Cutting edge: The Th1 response inhibits the generation of peripheral regulatory T cells. J Immunol 2010;184:30.
21. Liu G, Yang K, Burns S, et al. The S1P (1)-mTOR axis directs the reciprocal differentiation of T (H) 1 and T (reg) cells. Nat Immunol 2010;11:1047.
22. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 2005;80:110.
23. Ho IC, Hodge MR, Rooney JW, et al. The proto-oncogene c-maf is responsible for tissue-specific expression of interleukin-4. Cell 1996;85:973.
24. Kim JI, Ho IC, Grusby MJ, et al. The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity 1999;10:745.
25. Tanaka Y, So T, Lebedeva S, et al. Impaired IL-4 and c-Maf expression and enhanced Th1-cell development in Vav1-deficient mice. Blood 2005;106:1286.
26. Bluestone JA, Mackay CR, O'Shea JJ, et al. The functional plasticity of T cell subsets. Nat Rev Immunol 2009;9:811.
27. von Vietinghoff S, Ouyang H, Ley K. Mycophenolic acid suppresses granulopoiesis by inhibition of interleukin-17 production. Kidney Int 2010;78:79.
28. Zhang C, Zhang J, Yang B, et al. Cyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritis. Cytokine 2008;42:345.
29. Ha H, Kim MS, Park J, et al. Mycophenolic acid inhibits mesangial cell activation through p38 MAPK inhibition. Life Sci 2006;79:1561.
30. Park J, Ha H, Seo J, et al. Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Am J Transplant 2004;4:1982.
31. Huang HD, Liu ZH, Zhu XJ, et al. Inhibition of mycophenolic acid on NF-kappaB activity in human endothelial cells. Acta Pharmacol Sin 2002;23:649.
32. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-kappaB. J Biol Chem 1998;273:27467.
33. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467.
34. Cho ML, Ju JH, Kim KW, et al. Cyclosporine A inhibits IL-15-induced IL-17 production in CD4+ T cells via down-regulation of PI3K/Akt and NF-kappaB. Immunol Lett 2007;108:88.
35. Yuan X, Ansari MJ, D'Addio F, et al. Targeting Tim-1 to overcome resistance to transplantation tolerance mediated by CD8 T17 cells. Proc Natl Acad Sci USA 2009;106:10734.
36. Doreau A, Belot A, Bastid J, et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009;10:778.
37. Cua DJ, Tato CM. Innate IL-17-producing cells: The sentinels of the immune system. Nat Rev Immunol 2010;10:479.
38. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T (H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007;8:967.
39. McGeachy MJ, Chen Y, Tato CM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009;10:314.